New drug duo aims to fight Hard-to-Treat cancers

NCT ID NCT07276373

Recruiting now Disease control Sponsor: Corcept Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This study tests a new drug called nenocorilant combined with the immunotherapy nivolumab in people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 50 participants will take part in this early-stage trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nenocorilant (a drug) combined with nivolumab (an immunotherapy)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is an early-phase trial with only 50 participants, so results may not apply broadly. The combination could cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS

Contacts and locations

Locations

Site 01
RECRUITING

San Antonio, Texas, 78229, United States
Site 02
RECRUITING

West Valley City, Utah, 84119, United States
Site 03
RECRUITING

Los Angeles, California, 90025, United States
Site 04
RECRUITING

Grand Rapids, Michigan, 49546, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.